Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Chief Financial Officer | February 20, 2024 | February 22, 2024 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | CHIEF FINANCIAL OFFICER | September 01, 2026 | September 02, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Financial Officer | March 20, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2024 · Filed February 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,224 |
Reported balance
After 2024-02-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-20 · Grant · Acquired 33,000 · Balance 59,224 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. F2: Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2034-02-19 | Direct | 153,000 |
Reported balance
After 2024-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-20 · Grant · Acquired 153,000 · Balance 153,000 F3: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share.
F3: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
Olema Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2036-08-31 | Direct | 650,000 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 650,000 · Balance 650,000 F1: 25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Vir Biotechnology, Inc.
Report date March 20, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,115 |
Reported balance
After 2026-03-20 transaction · row 1
1 source rowRow 1 · 2026-03-20 · Other · Disposed 2,500 · Balance 160,115 F1: Transfer without consideration for estate planning purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,500 |
Reported balance
After 2026-03-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-03-20 · Other · Acquired 2,500 · Balance 2,500 F1: Transfer without consideration for estate planning purposes. F2: The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees. |
Filing footnotes · ownership attribution and instrument terms
F1: Transfer without consideration for estate planning purposes.
F2: The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 20:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001871145-26-000006 · form4-09022026_040901.xml · derivative · entry 1 O'Byrne Jason · CIK 0001871145 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2036-08-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 19:49 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-020480 · wk-form4_1774295389.xml · nonDerivative · entry 2 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,500 F1 · kind: Transfer without consideration for estate planning purposes. F2 · ownership.nature: The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 19:49 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-020480 · wk-form4_1774295389.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,115 F1 · kind: Transfer without consideration for estate planning purposes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,634 | $9.53 | $15,576.27 |
DisclosureSEC source: 0001628280-26-012395 · wk-form4_1772142937.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,615 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 00:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,089 | $7.45 | $15,568.90 |
DisclosureSEC source: 0001628280-26-011330 · wk-form4_1771978342.xml · nonDerivative · entry 2 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,249 F3 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001628280-26-011330 · wk-form4_1771978342.xml · derivative · entry 3 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-02-21 F4 · derivative.exercise_date: 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011330 · wk-form4_1771978342.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,338 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · balance_after: Includes 637 shares of common stock acquired by the Reporting Person on November 28, 2025, pursuant to an employee stock purchase program. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 19:47 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,799 | $5.56 | $37,782.04 |
DisclosureSEC source: 0001628280-25-052841 · wk-form4_1763495228.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,701 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. F2 · balance_after: Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001628280-25-007703 · wk-form4_1740516057.xml · derivative · entry 2 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:41 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007703 · wk-form4_1740516057.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,000 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 18:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001628280-24-048230 · wk-form4_1731954966.xml · derivative · entry 2 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-11-14 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on November 15, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 18:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-048230 · wk-form4_1731954966.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 F1 · acquired: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 153,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006433 · wk-form4_1708640897.xml · derivative · entry 2 O'Byrne Jason · CIK 0001871145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 153,000 shares Expires 2034-02-19 F3 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006433 · wk-form4_1708640897.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,224 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. F2 · balance_after: Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:47 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 131,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000017 · wf-form4_167718882178453.xml · derivative · entry 1 O'Byrne Jason · CIK 0001871145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 00:27 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 24,336 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-22-007860 · doc4.xml · derivative · entry 2 O'Byrne Jason · CIK 0001871145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,865 Underlying: Common Stock · 24,336 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to this option vested on February 8, 2022 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter until the option is fully vested on February 8, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 00:27 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 24,336 | $4.11 | $100,020.96 |
DisclosureSEC source: 0001209191-22-007860 · doc4.xml · nonDerivative · entry 1 O'Byrne Jason · CIK 0001871145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:35 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 147,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001209191-21-070819 · doc4.xml · derivative · entry 1 O'Byrne Jason · CIK 0001871145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2031-12-19 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.